Lutetium-177 PSMA-617
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LUTETIUM-177-PSMA |
|---|---|
| Type | Drug |
| Aliases | PluvictoЛютецій-177 PSMA-617 |
| Status | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | PSMA-targeted radioligand (β-emitter) |
|---|---|
| Mechanism | Small-molecule PSMA-binding ligand conjugated to β-emitting radionuclide Lu-177. PSMA is expressed on >90% of prostate adenocarcinoma cells; Lu-177-PSMA-617 binds PSMA and delivers cytotoxic β-radiation directly to tumor sites. Requires PSMA-PET-positive disease for selection (VISION criteria). |
| Typical dosing | 7.4 GBq IV q6 weeks × 6 cycles (VISION protocol). Administered in nuclear medicine / radioligand therapy unit with appropriate radiation safety. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
VISION trial: significant rPFS + OS benefit in PSMA-PET-positive mCRPC post-ARPI + post-taxane. Requires nuclear medicine infrastructure + PSMA-PET availability — limits access in Ukraine to a few centers.
Used By
Contraindications
CI-PROSTATE-LUTETIUM-VISCERAL-ONLY- CI-PROSTATE-LUTETIUM-VISCERAL-ONLY
Regimens
REG-LUTETIUM-PSMA- Lutetium-177 PSMA-617 radioligand therapy